Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Progress achieved on company's ongoing business and portfolio review Completed review of growth businesses within the Medical Segment: investing in and further developing at-Home Solutions and OptiFreight® Logistics as part of the company's portfolio for long-term growth and value creation Review of Global Medical Products and Distribution business continues, with focus on driving operational performance through the Medical Improvement Plan Reorganizing leadership structure to continue company's simplification efforts, prioritize core operational execution and drive efficiencies, accountability and transparency Updated enterprise operating and segment reporting structure, effective January 1, 2024, to be reflected in company's financial reporting beginning third quarter fiscal 2024 Providing pro-forma long-term financial targets for updated segment reporting structure Updated fiscal 2024 non-GAAP diluted EPS guidance to high end of $6.75 to $7.00 range Primarily driven by favorability in Interest and Other and Diluted Weighted Average Shares Outstanding, enabled by continued strong cash flow generation and incremental share repurchase during second quarter fiscal 2024 Further updates and details to be provided on February 1 during fiscal 2024 Q2 earnings call DUBLIN, Ohio , Jan. 9, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced progress on the company's ongoing business and portfolio review, including an updated enterprise operating and segment reporting structure, and an update to its fiscal year 2024 non-GAAP diluted earnings per share (EPS) outlook. These updates build upon the company's momentum, focus on long-term value creation, and continued actions to become more streamlined and focused.

Cardinal Health Announces Progress on Business and Portfolio Review and Fiscal 2024 Outlook Update

Apple

Everest Group Ltd

International Paper

Regeneron Pharmaceuticals

The S&P 500 had the worst start to a year since 2016, reflecting a sharp reversal of the roaring rally in the final two months of 2023. Despite the losses, some stocks in the ETF stood tall.

5 Stocks in S&P 500 ETF That Braved the Worst Start Since 2016

Fabrinet

Live Oak Bancshares

Marriott

Wingstop

The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You may buy LOB, MAR, CAH, FN and WING.

5 Low-Leverage Stocks to Buy Amid Mixed Investor Sentiments

DUBLIN, Ohio , Jan. 2, 2024  /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2024 on February 1, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m.

Cardinal Health to Announce Second-Quarter Results for Fiscal Year 2024 on February 1

Smith & Wesson Brands

Warner Bros Discovery Inc

Because buying dividend stocks is such a successful investment strategy over the past 100 years I gravitate towards them in my portfolio. It means I also look for stocks that have a proven track record of raising their payouts over time.

Will My Portfolio's Top 3 Performing Stocks From 2023 Deliver Again in 2024?

Exact Sciences

Haemonetics

Penumbra

Insulet

Stocks such as HAE, PEN, EXAS, PODD and CAH are set to garner remarkable growth for investors.

5 Impressive MedTech Industry Growth Stocks to Buy for 2024

Atmos Energy

NextEra Energy

Some of the dividend aristocrats, such as Cardinal Health (CAH), Atmos Energy (ATO) and NextEra Energy (NEE), have a better-quality business and strong underlying fundamentals.

3 Top Dividend Aristocrats to Buy Ahead of 2024

AbbVie

Abbott Labs

Archer-Daniels-Midland Company

Automatic Data Processing

Aflac

Albemarle

Amcor Plc

A. O. Smith

Air Products and Chemicals

Becton, Dickinson and Co.

Franklin Resources

Brown & Brown

Caterpillar

Chubb

Church & Dwight

C.H. Robinson Worldwide

Cincinnati Financial

Colgate-Palmolive

Clorox

Cintas Corp

Chevron

Dover

Ecolab

The S&P 500 Dividend Aristocrats Index contains 67 dividend growth stocks called the Dividend Aristocrats. I rank the Dividend Aristocrats by quality score and provide undervalued stocks for further research and investment.

29 Undervalued Dividend Aristocrats: December 2023

Cardinal Health is a global healthcare company that operates in over 40 countries and covers pharmaceutical distribution and medical products. Based on strong Q1 earnings, the Company is growing on multiple fronts. In addition, cost mitigation is starting to drive results in widening margins. With a price target of $115 and mitigated risks, CAH is a buy.

Cardinal Health Is Setting Up For A Great 2024

American Airlines

ABM Industries

Cleveland-Cliffs

Cencora Inc

We believe that stocks like American Airlines (AAL), ABM Industries (ABM), Cardinal Health (CAH), Cleveland-Cliffs (CLF) and Cencora (COR) should be on an investor's watchlist.

5 Broker-Favorite Stocks to Keep an Eye on as 2024 Approaches

Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Cardinal Health, Inc. (CAH) Hit a 52 Week High, Can the Run Continue?

Cardinal (CAH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Cardinal (CAH) Upgraded to Buy: Here's What You Should Know

Andersons

Avnet

Brinker International

Group 1 Automotive

We believe that stocks like Brinker International (EAT), Cardinal Health (CAH), The Andersons (ANDE), Avnet (AVT) and Group 1 Automotive (GPI) should be on an investor's watchlist.

5 Broker-Friendly Stocks to Keep an Eye on Amid Volatility

Assurant

Cboe Global Markets

FedEx

Installed Building Products

Cboe Global (CBOE), Cardinal Health (CAH), Assurant (AIZ), Installed Building Products (IBP) and FedEx (FDX) have a strong dividend growth potential.

5 Dividend Stocks Having Strong Growth Potential

Agilent Technologies

Accenture Plc

AGCO

Allstate

Applied Materials

American Tower

Ball Corp

Celanese

D.R. Horton

Dick's Sporting Goods

Diamondback Energy

Microsoft

PulteGroup

Steel Dynamics

Target

Visa

W. R. Berkley

We explain why selling cash-covered puts and covered calls are relatively safe choices for earning a high income. We will discuss how to formulate a sustainable and repeatable options income strategy. In this monthly series, we present how to go about selecting the right kind of stocks for options income. We present two lists of 10 stocks with multiple scenarios: PUT options, CALL options, and deep-in-the-money CALL options.

Earn A Potential 10% Plus Income With Options (December 2023)

News for Cardinal Health Stock (CAH)